Archive:
What about the “rare” ones in Germany? To clarify this question, the company Genzyme invited people to a press conference on the occasion of Rare Disease Day. Among others, two physicians reported at the event on their clinical practice in the diagnosis and treatment of orphan diseases. Both in detail - using the example of the diagnosis of Pompe disease - and in general - with regard to the treatment of rare metabolic disorders - the lectures showed that the care for patients with rare diseases in Germany is not sufficient. The error lies in the system – and in the lack of networking between the players.
28.05.2013
In der Podiumsdiskussion „Wege aus dem Innovationsstau“ wurde unter Moderation von Prof. Dr. Dr. Alfred Holzgreve (Vivantes) die erste Vortragssession resümiert. Es dikutierten die Vortragenden Dr. Stefan Etgeton (Bertelsmann Stiftung), Prof. Dr. Bertram Häussler (IGES Institut), Prof. Dr. Wolfgang Greiner (Universität Bielefeld), Prof. Dr. Neugebauer (IFOM, Köln), es meldeten sich zu Wort Helmut Hildebrandt (OptiMedis) und Antje Domscheit (BVA).
28.05.2013
To promote innovative cross-sectoral forms of care and for health care research, an innovation fund financed by the health insurance companies is to be created, 75 percent of which will flow into research into the content of standard care and a quarter into health care research. That's at least 75 million euros for health services research alone, far less than the German Network for Health Services Research and the Health Advisory Council have been calling for around 300 million euros for many years, but still. Josef Hecken, the impartial chairman of the Federal Joint Committee, has already announced that the first money from this fund should flow in the second half of 2014. The question will be: where does this money go? And: What exactly should be researched? Will it be outcome-driven research that works top down from the most important to the less important topics. Incidentally, such a maxim for action was included in the key points paper of a “National Action Plan for Health Services Research”, which was presented jointly by the German Network for Health Care Research and the Bertelsmann Foundation in the Bertelsmann representative office at Unter den Linden 1, the former commandant's house in Berlin, the very room in which the 4th The specialist congress of “Monitor Healthcare Research” took place under the title “Innovation 2014” and in cooperation with the Bertelsmann company arvato healthcare and the BKK umbrella organization.
28.05.2013
If you enter the keyword “integrated care” into Google, you get 470,000 hits – the term “standard care” leads to 443,000 results. This numerical ratio reflects well the health policy discussions of the last few years. However, it is far from a reflection of the supply landscape. 14 years after the introduction of IV, it still has a niche existence in the German health system. In recent years, only 0.7 to 0.8 percent of health spending has flowed into integrated care. In addition, the number of IV contracts has been stagnating for years. This leaves considerable untapped potential for a better and more efficient healthcare system.
28.05.2013
As the US health economist Prof. Dr. Uwe E. Reinhardt, Princeton University, who last spoke at an annual congress of the Federal Managed Care Association, criticized above all that the health policy debate in Germany is always about income distribution, not about patients. That was in September 2000. In January 2014 he was back again, calling Obamacare a “disgusting Band-Aid for a disgusting system” at the BMC convention. “Monitor Healthcare Research” spoke to the controversial economist, who didn’t mince his words: “The president and his people have failed as project managers.”
28.05.2013
When it comes to medication provision, there are clear differences between private and statutory health insurance. The latest figures are provided by the current study by the Scientific Institute of PKV (WIP) on “Medicine supply for privately insured people 2012”. The analysis shows clear differences in drug prescribing practices, which demonstrate greater freedom of choice and therapy as well as innovation-friendliness in private health insurance. The WIP drug study provides a comprehensive analysis of the PKV drug market. It closes a gap in the drug prescription report, which can only reflect the events of the statutory health insurance.
28.05.2013
Few topics currently occupy Berlin's health policy circles as intensely as the innovation fund announced in the coalition agreement. Claims are being made or denied, and numerous models for the process of distributing the funds are being developed. Many questions remain open and are being hotly debated.
28.05.2013
Als der US-Gesundheitsökonom Prof. Dr. Uwe E. Reinhardt, Princeton University, das letzte Mal auf einem Jahreskongress des Bundesverband Managed Care sprach, bemängelte er vor allem, dass sich in der gesundheitspolitischen Debatte in Deutschland alles immer nur um die Einkommensverteilung, nicht um die Patienten drehe. Das war im September 2000. >> Die ökonomische Evaluation ist ein technisches Hilfsmittel, um Entscheidungen über die Verwendung knapper Ressourcen zu erleichtern. Da Knappheit bedeutet, dass mehr Handlungsmöglichkeiten existieren als mit den verfügbaren Mitteln realisiert werden können, besteht das ökonomische Entscheidungsproblem vor allem darin, Klarheit zu gewinnen, auf welche Handlungsmöglichkeiten verzichtet wird bzw. welche Bedürfnisse nachrangig befriedigt werden sollen. Der Entscheidungsträger wird sich seiner Ziele und Erwartungshaltungen folglich umso klarer bewusst werden müssen, je schärfer die materiellen Restriktionen seines Handelns sind.Januar 2014 war er wieder da und betitelte auf dem BMC-Kongress Obamacare als ein „ekliges Pflaster für ein ekliges System“. „Monitor Versorgungsforschung“ sprach mit dem streitbaren Ökonomen, der kein Blatt vor den Mund nahm: „Als Projektmanager haben der Präsident und seine Leute versagt.“
28.05.2013
For a few weeks now, doctors and hospitals have been able to participate in outpatient specialist medical care, or ASV for short, in accordance with Section 116b SGB V. To do this, they must apply to the specially set up extended state committees in their respective federal states. But are the newly formed extended state committees already sufficiently positioned from a know-how and manpower perspective? The question cannot be answered so easily because an overview has not yet been provided. Hospitals or doctors who want to apply for the ASV first had to do their own research into where and how they could do so; which becomes even more difficult when they supply supplies on the border of KV districts. That is why the Federal Association of Outpatient Specialist Medical Care (BV ASV) in cooperation with “Monitor Health Services Research” (MVF) ensures transparency at this point. “Monitor Health Care Research” spoke to the board of the Federal Association of Outpatient Specialist Medical Care, Dr. Axel Munte.
28.05.2013
After 18 lectures, a real tour de force from a wide variety of perspectives through three years of early benefit assessment, Josef Hecken, impartial chairman of the Federal Joint Committee, ventured a summary of the G-BA's AMNOG conference, which also served as an assessment of the status of a possible further development of the now established , but the details may still be controversial; all the more so because the Federal Committee is the absolute master of this process, which can now process and accept the suggested suggestions, criticisms raised and detailed improvements. Or not.